Publication date: Feb 04, 2025

Elevated glycosylated hemoglobin (HbA1c) in individuals with type 2 diabetes is associated with increased risk of hospitalization and death after acute COVID-19, however the effect of HbA1c on Long COVID is unclear. Evaluate the association of glycemic control with the development of Long COVID in patients with type 2 diabetes (T2D). We conducted a retrospective cohort study using electronic health record data from the National COVID Cohort Collaborative. Our cohort included individuals with T2D from eight sites with longitudinal natural language processing (NLP) data. The primary outcome was death or new-onset recurrent Long COVID symptoms within 30-180 days after COVID-19. Symptoms were identified as keywords from clinical notes using NLP in respiratory, brain fog, fatigue, loss of smell/taste, cough, cardiovascular and musculoskeletal symptom categories. Logistic regression was used to evaluate the risk of Long COVID by HbA1c range, adjusting for demographics, body mass index, comorbidities, and diabetes medication. A COVID-negative group was used as a control. Among 7430 COVID-positive patients, 1491 (20. 1%) developed symptomatic Long COVID, and 380 (5. 1%) died. The primary outcome of death or Long COVID was increased in patients with HbA1c 8% to

Open Access PDF

Semantics

Original Article